论文部分内容阅读
探讨免疫疗法联合拉米夫定对慢性乙型肝炎(CHB)的抗病毒治疗效果。方法治疗组(免疫疗法+拉米夫定)76例,对照组(单用拉米夫定)38例。2组病例根据血清ALT、HBV标志物水平分为免疫耐受期、免疫清除期。免疫疗法包括应用乙型肝炎疫苗、绿脓杆菌菌毛注射液、胸腺肽注射液。结果免疫清除期病例的HBeAg阴转率治疗组为15/34(44.1％),对照组为2/17(11.8％),P<0.05。HBV DNA阴转率2组分别为82.5％和70.6％。免疫耐受期病例的HBeAg阴转率治疗组为11/42(26.2％),对照组1/21(4.8％),P<0.05 HBVDNA阴转率治疗组为23/42(54.8％),对照组6/21(28.6％),P<0.05。结论免疫疗法联合拉米夫定可以提高CHB患者HBeAg及HBV DNA阴转率。
To investigate the effect of immunotherapy combined with lamivudine in antiviral treatment of chronic hepatitis B (CHB). Methods The treatment group (immunotherapy + lamivudine) 76 cases, control group (lamivudine alone) 38 cases. Two groups of patients based on serum ALT, HBV markers were divided into immune tolerance period, immune clearance period. Immunotherapy includes the use of hepatitis B vaccine, Pseudomonas aeruginosa pili injection, thymosin injection. Results In the immunostaining cases, the rate of HBeAg negative conversion rate was 15/34 (44.1%) in the treatment group and 2/17 (11.8%) in the control group, P <0.05. HBV DNA negative rate of two groups were 82.5% and 70.6%. HBeAg negative rate in immunocompromised patients was 11/42 (26.2%) in the treatment group, 1/21 (4.8%) in the control group, and 23/42 (54.8%) in the negative rate of HBVDNA treatment group Group 6/21 (28.6%), P <0.05. Conclusion Immunotherapy combined with lamivudine can improve HBeAg and HBV DNA negative rate in CHB patients.